XML 63 R46.htm IDEA: XBRL DOCUMENT v3.3.1.900
Stock-Based Compensation (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 02, 2014
May. 31, 2014
USD ($)
Jun. 30, 2014
USD ($)
Dec. 31, 2015
USD ($)
installment
item
shares
Dec. 31, 2014
USD ($)
shares
Dec. 31, 2013
USD ($)
Dec. 31, 2011
shares
Stock-based compensation              
Stock-based compensation expense       $ 6,873,000 $ 27,390,000 $ 25,687,000  
Number of shares of Theravance Biopharma issued for every share of Theravance 0.286            
Performance-contingent              
Stock-based compensation              
Outstanding (in shares) | shares       1,305,000 1,772,000    
Employee Stock Purchase Plan              
Stock-based compensation              
Shares remaining available for issuance | shares       265,711      
Purchase price as a percentage of fair market value of stock       85.00%      
Consecutive and overlapping offering periods       24 months      
Number of offering periods | item       4      
Duration of purchase period       6 months      
Maximum contributions as a percentage of employee's eligible compensation       15.00%      
Maximum number of shares an employee may purchase during any purchase period | shares       2,500      
Maximum value of shares an employee may purchase       $ 25,000      
Stock-based compensation expense       129,000 $ 10,000 536,000  
RSAs              
Stock-based compensation              
Stock-based compensation expense       2,850,000 7,575,000 9,723,000  
RSAs | Performance-contingent              
Stock-based compensation              
Stock-based compensation expense       613,000 10,580,000 1,061,000  
RSUs              
Stock-based compensation              
Stock-based compensation expense       $ 2,492,000 $ 4,564,000 10,174,000  
Outstanding (in shares) | shares       459,000 775,000    
Additional disclosures              
Incremental stock-based compensation expense arising out of spin-off     $ 1,200,000        
Share based compensation expense included in discontinued operations     $ 900,000        
RSUs | Non-employee director              
Additional disclosures              
One time grant of shares value       $ 250,000      
Pro rata shares grant value       $ 250,000      
Number of annual installments | installment       2      
RSUs | Performance-contingent              
Stock-based compensation              
Stock-based compensation expense       $ 0 $ 3,000 $ 61,000  
Outstanding (in shares) | shares       0      
2012 Equity Incentive Plan              
Stock-based compensation              
Shares remaining available for issuance | shares       3,466,041      
Special Long-Term Retention and Incentive Cash Awards Program | RSAs | Performance-contingent              
Stock-based compensation              
Shares of common stock approved and authorized for issuance | shares             1,290,000
Timeframe for achievement of performance conditions             6 years
Stock-based compensation expense   $ 7,000,000          
Outstanding (in shares) | shares       63,000